GLAXOSMITHKLINE ΜΟΝΟΠΡΟΣΩΠΗ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ Δ.Τ. GLAXOSMITHKLINE ΜΟΝΟΠΡΟΣΩΠΗ Α - αποτελεσματα

havrix 1440 eu/ml injektionsvæske, suspension

glaxosmithkline pharma a/s - hepatitis a virus, stamme hm 175 (inaktiveret) - injektionsvæske, suspension - 1440 eu/ml

imigran 12 mg/ml injektionsvæske, opløsning

glaxosmithkline pharma a/s - sumatriptansuccinat - injektionsvæske, opløsning - 12 mg/ml

imigran 10 mg næsespray, opløsning

glaxosmithkline pharma a/s - sumatriptan - næsespray, opløsning - 10 mg

imigran 20 mg næsespray, opløsning

glaxosmithkline pharma a/s - sumatriptan - næsespray, opløsning - 20 mg

imigran sprint 100 mg dispergible tabletter

glaxosmithkline pharma a/s - sumatriptansuccinat - dispergible tabletter - 100 mg

lamictal 100 mg tyggetabletter/dispergible tabletter

glaxosmithkline pharma a/s - lamotrigin - tyggetabletter/dispergible tabletter - 100 mg

lamictal 200 mg tyggetabletter/dispergible tabletter

glaxosmithkline pharma a/s - lamotrigin - tyggetabletter/dispergible tabletter - 200 mg

lamictal 25 mg tyggetabletter/dispergible tabletter

glaxosmithkline pharma a/s - lamotrigin - tyggetabletter/dispergible tabletter - 25 mg

lamictal 50 mg tyggetabletter/dispergible tabletter

glaxosmithkline pharma a/s - lamotrigin - tyggetabletter/dispergible tabletter - 50 mg

lamictal 5 mg tyggetabletter/dispergible tabletter

glaxosmithkline pharma a/s - lamotrigin - tyggetabletter/dispergible tabletter - 5 mg